Current Oncology | Free Full-Text | A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer | Nature Communications
PRIMA Study | ZEJULA (niraparib)
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆ - ScienceDirect
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us? - ppt download
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
ENGOT-OVAR16/NOVA
SGO 2023: Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab - ScienceDirect
g48831msi014.gif
Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study | Future Oncology
Oncology Grand Rounds: Part 3 — PARP Inhibitors in Ovarian Cancer | Research To Practice
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial - ScienceDirect
![PDF] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d8a6a7200a9b92c47e5ad3f2c4468f771fe2cb38/4-Figure2-1.png "PDF] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial | Semantic Scholar")
PDF] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial | Semantic Scholar
NOVA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial - The Lancet Oncology
![PDF] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d8a6a7200a9b92c47e5ad3f2c4468f771fe2cb38/3-Figure1-1.png "PDF] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial | Semantic Scholar")
PDF] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial | Semantic Scholar
Tesaro begins phase III trial of niraparib for treatment of ovarian cancer – All About Drugs
Niraparib - Zejula als onderhoudsbehandeling bij gevorderde eierstokkanker geeft een veel langere progressievrije overleving bij zowel patiënten met BRCA-gemuteerde eierstokkanker als bij niet BRCA-gemuteerd
An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions | SpringerLink
An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions | SpringerLink
A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
Case Discussion: Second Opinion - ppt download
Clinical trials results for Niraparib in OC. | Download Scientific Diagram
